他汀类药物对70例肺栓塞患者预后的影响

doi:10.6040/j.issn.1671-7554.0.2020.0356

摘要/Abstract

摘要： 目的分析他汀类药物对肺栓塞患者预后的影响。方法回顾性分析2013年8月1日至2019年8月15日于西南医科大学附属医院住院并首诊为肺栓塞的162例患者的临床资料。根据他汀类药物使用情况分为他汀组(n=70)及非他汀组(n=92)。随访截止时间为2019年9月15日,终点事件为全因死亡。采用Kaplan-Meier法绘制生存曲线及Log-rank检验比较两组生存曲线,将终点事件与使用他汀类药物及基础疾病等行单因素及多因素Cox回归模型分析。结果随访期间患者死亡共39例,病死率24.07%;其中,他汀组患者死亡9例,非他汀组患者死亡30例。单因素Cox分析结果表明,对肺栓塞患者预后有意义的指标包括入院年龄、恶性肿瘤、使用他汀类药物、HDL水平、LDL水平、TC水平。在调整年龄、恶性肿瘤、HDL等因素后,多因素Cox回归模型分析显示,使用他汀类药物治疗对肺栓塞患者预后有保护作用(P=0.009, HR=0.348, 95%CI: 0.158~0.766)。结论使用他汀类药物治疗方案可改善肺栓塞患者预后。

关键词: 肺栓塞, 他汀, 预后

Abstract: Objective To investigate the effect of statins on the patients with pulmonary embolism. Methods From Aug. 1^st, 2013 to Aug. 15^th, 2019, the clinical data of 162 patients with initial diagnosis of pulmonary embolism admitted to the Affiliated Hospital of Southwest Medical University were retrospectively screened. According to the use of statins, the patients were divided into statin group(n=70)and non-statin group(n=92). The deadline of follow-up was Sep. 15^th, 2019. The end-event was all-cause death. Kaplan-Meier method was applied to draw the survival curves of two groups which were compared by Log-rank test. Univariate and multivariate Cox proportional hazards regression model were performed to analyze of end-event, use of statins and underline disease, etc. Results During follow-up period, 39 patients(24.07%)died by all-cause, among whom, 9 cases were in statin group and 30 cases were in non-statin group. Univariate Cox proportional hazards regression model analysis showed that age, history of malignancy, use of statins, HDL level, LDL level and TC level influenced the prognosis of patients. After adjustment of age, history of malignancy, HDL level and other factors, multivariate Cox proportional hazards regression model analysis concluded that use of statins had a protective effect on the prognosis of patients with pulmonary embolism(P=0.009, HR=0.348, 95%CI: 0.158-0.766). Conclusion The use of statins can improve prognosis of patients with pulmonary embolism.

Key words: Pulmonary embolism, Statin, Prognosis

中图分类号:

R563.5

姚宇,王文军,梁玉灵. 他汀类药物对70例肺栓塞患者预后的影响[J]. 山东大学学报 (医学版), 2020, 58(11): 76-80.

YAO Yu, WANG Wenjun, LIANG Yuling. Effect of stains on the prognosis of 70 patients with pulmonary embolism[J]. Journal of Shandong University (Health Sciences), 2020, 58(11): 76-80.

参考文献

[1] 中华医学会呼吸病学分会肺栓塞与肺血管病学组,中国医师协会呼吸医师分会肺栓塞与肺血管病工作委员会,全国肺栓塞与肺血管病防治协作组.肺血栓栓塞症诊治与预防指南[J].中华医学杂志, 2018, 98(14): 1060-1087.
[2] Mohammad S, Nguyen H, Nguyen M, et al. Pleiotropic effects of statins: untapped potential for statin pharmacotherapy[J]. Curr Vasc Pharmacol, 2019, 17(3): 239-261.
[3] 段瑞生. 他汀对动脉粥样硬化的免疫调节及其在临床应用中的思考[J]. 山东大学学报(医学版), 2015, 53(5): 1-4. DUAN Ruisheng. Immune-regulation of statins in atherosclerosis and opinions on its clinical applications[J]. Journal of Shandong University(Health Sciences), 2015, 53(5): 1-4.
[4] Skajaa N, Szépligeti SK, Horváth-Puhó E, et al. Initiation of statins and risk of venous thromboembolism: population-based matched cohort study[J]. Thromb Res, 2019, 184: 99-104. doi: 10.1016/j.thromres.2019.11.003.
[5] Miksza JK, Zaccardi F, Kunutsor SK, et al. Statins and risk of thromboembolism: a meta-regression to disentangle the efficacy-to-effectiveness gap using observational and trial evidence[J]. Nutr Metab Cardiovasc Dis, 2019, 29(10): 1023-1029.
[6] Orsi FA, Biedermann JS, Kruip MJHA, et al. Rosuvastatin use reduces thrombin generation potential in patients with venous thromboembolism: a randomized controlled trial[J]. J Thromb Haemost, 2019, 17(2): 319-328.
[7] Kunutsor SK, Seidu S, Khunti K. Statins and primary prevention of venous thromboembolism: a systematic review and meta-analysis[J]. Lancet Haematol, 2017, 4(2): e83-e93. doi: 10.1016/S2352-3026(16)30184-3.
[8] 中华医学会心血管病学分会肺血管病学组,中国医师协会心血管内科医师分会. 急性肺血栓栓塞症诊断治疗中国专家共识[J].中华内科杂志, 2010, 49(1): 74-81.
[9] Turner RM, Yin P, Hanson A, et al. Investigating the prevalence, predictors, and prognosis of suboptimal statin use early after a non-ST elevation acute coronary syndrome[J]. J Clin Lipidol, 2017, 11(1): 204-214.
[10] Stewart LK, Sarmiento EJ, Kline JA. Statin use is associated with reduced risk of recurrence in patients with venous thromboembolism[J]. Am J Med, 2020, 133(8): 930-935.
[11] Yoshikawa Y, Yamashita Y, Morimoto T, et al. Effect of statins on recurrent venous thromboembolism(from the COMMAND VTE registry)[J]. Am J Cardiol, 2020, 125(2): 189-197.
[12] Tagalakis Vi, Eberg M, Kahn S, et al. Use of statins and reduced risk of recurrence of VTE in an older population. A population-based cohort study[J]. Thromb Haemost, 2016, 115(6): 1220-1228.
[13] Kronenberg RM, Beglinger S, Stalder O, et al. Statin therapy and recurrent venous thromboembolism in the elderly: a prospective cohort study[J]. Sci Rep, 2019, 9(1): 14804. doi: 10.1038/s41598-019-51374-8.
[14] 中国成人血脂异常防治指南修订联合委员会.中国成人血脂异常防治指南(2016年修订版)[J].中华心血管病杂志, 2016, 44(10): 833-853.
[15] Eichinger S, Pecheniuk NM, Hron G, et al. High-density lipoprotein and the risk of recurrent venous thromboembolism[J]. Circulation, 2007, 115(12): 1609-1614.
[16] Olsson AG, Schwartz GG, Szarek M, et al. High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial[J]. Eur Heart J, 2005, 26(9): 890-896.
[17] Siniscalchi C, Quintavalla R, Rocci A, et al. Statin and all-cause mortality in patients receiving anticoagulant therapy for venous thromboembolism. Data from the RIETE registry[J]. Eur J Intern Med, 2019, 68: 30-35. doi: 10.1016/j.ejim.2019.07.028.
[18] Mohammad S, Nguyen H, Nguyen M, et al. Pleiotropic effects of statins: untapped potential for statin pharmacotherapy[J]. Curr Vasc Pharmacol, 2019, 17(3): 239-261.
[19] Wu K, Tian S, Zhou H, et al. Statins protect human endothelial cells from TNF-induced inflammation via ERK5 activation[J]. Biochem Pharmacol, 2013, 85(12): 1753-1760.
[20] McGuire TR, Kalil AC, Dobesh PP, et al. Anti-inflammatory effects of rosuvastatin in healthy subjects: a prospective longitudinal study[J]. Curr Pharm Des, 2014, 20(7): 1156-1160.
[21] Whitehead NP, Kim MJ, Bible KL, et al. A new therapeutic effect of simvastatin revealed by functional improvement in muscular dystrophy[J]. Proc Natl Acad Sci U S A, 2015, 112(41): 12864-12869.
[22] Nazli Y, Colak N, Alpay MF, et al. Neuroprotective effect of atorvastatin in spinal cord ischemia-reperfusion injury[J]. Clinics, 2015, 70(1): 52-60.
[23] Luzak B, Rywaniak J, Stanczyk L, et al. Pravastatin and simvastatin improves acetylsalicylic acid-mediated in vitro blood platelet inhibition[J]. Eur J Clin Invest, 2012, 42(8): 864-872.
[24] Orsi FA, Cannegieter SC, Lijfering WM. Statin therapy to revert hypercoagulability and prevent venous thromboembolism: a narrative review[J]. Semin Thromb Hemost, 2019, 45(8): 825-833.
[25] 代丽, 吴尚洁. 阿托伐他汀抑制RhoA/Rho激酶活性逆转低氧性肺动脉高压大鼠肺动脉高压和肺血管重构[J]. 中南大学学报(医学版), 2011, 36(1): 58-63. DAI Li, WU Shangjie. Atorvastatin attennates hypoxic pulmonary hypertension in rats by inhibiting RhoA/Rho kinase pathway[J]. Journal of Central South University(Medical Science), 2011, 36(1): 58-63.

相关文章 15

[1]	徐宁宇王磊郝恩魁苏国海. STEMI患者急诊PCI前口服阿托伐他汀对炎症介质及左心室功能的影响[J]. 山东大学学报(医学版), 2209, 47(6): 69-72.
[2]	高秀蕊臧恒昌. 复方烟酸辛伐他汀双层片体外释放度的研究[J]. 山东大学学报(医学版), 2209, 47(6): 109-113.
[3]	李梓绮,魏闫若雪,刘晓晗,刘春铖,赵然,刘玉昆. 长链非编码RNA HEATR3反义RNA 1参与结直肠癌发生发展的功能及其临床意义[J]. 山东大学学报 (医学版), 2025, 63(9): 108-115.
[4]	刘保国,宋翔,赵晓文,毛亚丽. 血清STAT5B、NKAIN1 mRNA检测在乳腺癌中的应用价值[J]. 山东大学学报 (医学版), 2025, 63(7): 68-74.
[5]	王磊,常霄,王梓萌,李娇娇,崔书君,杨飞,朱月香. 瘤内及瘤周DCE-MRI影像组学对宫颈癌患者无进展生存期的预测价值[J]. 山东大学学报 (医学版), 2025, 63(6): 45-54.
[6]	贾若曦,吕丽,刘涵云,吴寅平,李凤彩,赵泽华,王凯,范玉琛. 血细胞计数相关标志物对慢加急性乙型肝炎肝衰竭患者28天预后的诊断价值[J]. 山东大学学报 (医学版), 2025, 63(6): 89-99.
[7]	杜雪,李春霞,刘云霞,张涛. 基于MFPC-Cox的结直肠癌患者预后动态预测模型[J]. 山东大学学报 (医学版), 2025, 63(5): 101-110.
[8]	杨卫芳,徐宏,刘元涛,赵蕙琛. 促甲状腺激素受体抗体在Graves病复发中的作用机制及其临床意义[J]. 山东大学学报 (医学版), 2025, 63(4): 116-121.
[9]	刘文钊,张远,马湘萍,魏峰涛,卜培莉. 内皮活化和应激指数预测值与心力衰竭患者死亡风险的关联[J]. 山东大学学报 (医学版), 2025, 63(11): 27-35.
[10]	陈文亮,王欢欢,郝金锦,弓蕊,赵强,张飞,高磊,董静逊. lncRNA PVT1表达在胃癌预后评估及恶性进展中的作用:基于列线图模型与细胞功能实验的研究[J]. 山东大学学报 (医学版), 2025, 63(10): 61-71.
[11]	郭姝画,樊扬,田风,王传新,杜鲁涛,李培龙,郭兴,徐硕. 微原纤维相关蛋白3在调控胶质瘤干细胞间充质表型转化中的作用[J]. 山东大学学报 (医学版), 2024, 62(6): 9-16.
[12]	吴彤,杨晶玉,林盪,徐婉茹,曾宇鋆. 基于孟德尔随机化方法探讨脂质和降脂药物与慢性阻塞性肺病的遗传关联[J]. 山东大学学报 (医学版), 2024, 62(5): 54-63.
[13]	魏闫若雪,李梓绮,刘春铖,刘晓晗,赵然,刘玉昆. 结直肠癌中SP1的瘤内异质性表达及其临床意义[J]. 山东大学学报 (医学版), 2024, 62(5): 89-94.
[14]	刘春铖,刘晓晗,魏闫若雪,李梓绮,刘玉昆,赵然. 结直肠癌中含溴结构域蛋白9的亚细胞定位模式及其临床意义[J]. 山东大学学报 (医学版), 2024, 62(4): 24-30.
[15]	杨雪彦,吴寅平,吕丽,赵泽华,马行宇,李凤彩,王凯,范玉琛. 单核细胞与淋巴细胞比值动态变化对慢加急性乙型肝炎肝衰竭预后的诊断价值[J]. 山东大学学报 (医学版), 2024, 62(3): 61-69.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed